In April 2025, Kamau Therapeutics announced a study is a first-in-human, single-arm, open-label Phase I/II study of nula-cel ...

Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. Regulatory submissions are expected in 2026, and if ...

Gene therapy developer CRISPR Therapeutics AG (CRSP) is navigating some regulatory and commercial dynamics. Its flagship gene ...

ToolGen files patent infringement lawsuit against Vertex Pharma in UK for genome editing therapy CASGEVY: Seoul, South Korea Tuesday, April 22, 2025, 15:00 Hrs [IST] ToolGen, Inc.

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ®Seeks to expand licensing of its proprietary CRISPR RNP technologySEOUL, South Korea, April 21, 2025 /PRNewswi ...

ToolGen, Inc. (KOSDAQ 199800), led by CEO Jong Sang Ryu and recognized as a global leader in genome editing technology, announced today that it has filed a patent infringement lawsuit in the United Ki ...

Reshma Kewalramani is the only person of Indian-origin to find her way to the 2025 list. Kewalramani emigrated to the United ...

A federal district court had ruled in favor of HHS, restricting Vertex's ability to provide fertility preservation services to Medicaid patients.

The Advocate highlights social inequality through original stories and opinions, and content generated by fellow NNPA and other publications ...

Kewalramani becme the first female CEO of a large, public U.S. biotechnology company after immigrating from India at age 11 ...

Many high risk, high reward medical therapies that use cutting edge science are proving themselves in clinical trials. But are health services ready to pay for them—and how? Marianne Guenot reports On ...

Bluebird has reaffirmed its support for a proposed acquisition after Ayrmid failed to deliver a binding offer by the extended ...